Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Heron Therapeutics Inc. (HRTX:NASDAQ), powered by AI.
Heron Therapeutics Inc. is currently trading at $0.45. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Heron Therapeutics Inc. on Alpha Lenz.
Heron Therapeutics Inc.'s P/E ratio is -3.7.
“Heron Therapeutics Inc. trades at a P/E of -3.7 (undervalued) with strong ROE of 209.1%. 3Y revenue CAGR of 12.9% highlights clear growth momentum.”
Ask for details →Heron Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutic treatments to address unmet medical needs. The company's primary focus is on improving the lives of patients suffering from cancer and pain, aiming to enhance the efficacy and safety of treatments in these areas. Heron Therapeutics is notable for its work on innovative drug delivery methods, such as extended-release formulations that aim to optimize the therapeutic effects of medications while minimizing side effects. With a strong emphasis on clinical development, Heron operates at the intersection of pharmacology and patient care, pushing advancements particularly within oncology and postoperative pain management fields. The company’s contributions are significant within the healthcare sector, as they provide potential breakthroughs in the treatment paradigms of serious and prevalent conditions. Furthermore, Heron Therapeutics' innovations can influence both clinical practices and healthcare expenditures by potentially offering alternatives that improve patient outcomes and reduce the need for ongoing intervention.
“Heron Therapeutics Inc. trades at a P/E of -3.7 (undervalued) with strong ROE of 209.1%. 3Y revenue CAGR of 12.9% highlights clear growth momentum.”
Ask for details →Heron Therapeutics Inc. (ticker: HRTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 122 employees. Market cap is $76M.
The current price is $0.454 with a P/E ratio of -3.74x and P/B of 5.27x.
ROE is 209.08% and operating margin is -1.64%. Annual revenue is $155M.